Edward T Mathers
CIK 1328625 · EVP, Corporate Dev. & Venture · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$487.47M
Companies
19
Total Filings
83
Lifetime Open-Market Net
$47.23M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKUR | Director | 15,310 | $3.95 | $60.5K | $0 | 7 | 2026-06-08 |
| MBX | Director | 1,023,103 | $60.06 | $61.45M | $8.00M | 4 | 2026-06-05 |
| TRVI | Director | 948,948 | $18.43 | $17.49M | $0 | 9 | 2026-06-04 |
| RYTM | Director | 21,168 | $108.04 | $2.29M | $0 | 14 | 2026-03-16 |
| KRRO | 10%+ Owner | 1,297,893 | $10.50 | $13.63M | $3.30M | 2 | 2026-03-12 |
| SGP | 10%+ Owner | 6,035,038 | $21.62 | $130.48M | $15.00M | 1 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 488,982 | $16.35 | $7.99M | -$24.5K | 6 | 2025-10-06 |
| SNTI | Director | — | $0.38 | — | $0 | 5 | 2025-06-27 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| Inozyme Pharma, Inc. (INZY) Delisted | Director | — | $4.00 | — | $0 | 5 | 2024-06-20 |
| SVRA | 10%+ Owner | 24,471,264 | $5.33 | $130.43M | $1000.0K | 1 | 2023-07-19 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | — | $0.69 | — | $0 | 8 | 2023-06-26 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | Director | — | $18.20 | — | $0 | 3 | 2023-06-08 |
| Akouos, Inc. (AKUS) Delisted | Director | — | $13.29 | — | $0 | 3 | 2022-12-02 |
| MIRM | Director | — | $112.23 | — | $0 | 3 | 2022-06-06 |
| GLUE | 10%+ Owner | 5,973,296 | $22.04 | $131.65M | $19.95M | 1 | 2021-06-30 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | — | — | — | $0 | 4 | 2020-04-03 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | — | — | — | $0 | 1 | 2016-09-06 |
| MEDI | EVP, Corporate Dev. & Venture | — | $33.42 | — | $0 | 2 | 2007-06-19 |
Recent Filings · Page 2 of 9
83 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-02 | OKUR | Grant (A) | +4,694 | $0 | EDGAR |
| 2025-06-27 | SNTI | Grant (A) | — | $0 | EDGAR |
| 2025-06-26 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2025-06-23 | RYTM | Exer (M) | +4,000 | $0 | EDGAR |
| 2025-06-13 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | MBX | Grant (A) | — | $0 | EDGAR |
| 2025-05-30 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2025-04-02 | OKUR | Grant (A) | +2,580 | $0 | EDGAR |
| 2025-03-11 | SNTI | Grant (A) | — | $0 | EDGAR |
| 2024-10-08 | OKUR | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.